证券日报网讯 1月22日，国际医学在互动平台回答投资者提问时表示，本次非公开发行已经公司第十三 届董事会第九次会议、2025年第二次临时股东会审议通过，募集资金拟用于智慧康养项目、质子治疗中 心二期项目及补充流动资金。根据《上市公司募集资金监管规则》，公司募集资金使用应当专款专用。 任何对既定募投计划的重大调整，都必须严格遵循法定程序。有关本次发行的后续进展，请关注相关公 告。 （文章来源：证券日报） ...

Core Viewpoint - The company has confirmed that the funds raised from the private placement will be allocated specifically for the smart healthcare project, the second phase of the proton therapy center, and to supplement working capital, with no immediate plans to change the use of these funds for brain-computer interface research [1] Group 1 - The company responded to an investor inquiry regarding the potential change in the use of funds from the stock issuance, indicating that any significant adjustments to the fundraising plan must follow legal procedures [1] - The private placement has been approved by the company's board and shareholders, emphasizing the commitment to the original fundraising purposes [1] - The company expressed its ongoing interest in modern frontier medical technologies, including brain-computer interfaces, while maintaining a focus on building a high-level hospital [1]

Group 1 - The core viewpoint of the article is that International Medical has clarified its fundraising plan for the 2025 fiscal year, which will be used for specific projects and working capital [1] - The funds raised will be allocated to the Smart Health and Elderly Care Project, the Phase II Proton Therapy Center Project, and to supplement working capital [1] - The company emphasizes that the fundraising is compliant and does not involve any acquisition matters [1] Group 2 - The company assures that it strictly adheres to laws, regulations, and regulatory requirements to ensure proper corporate governance [1] - All significant matters will be disclosed in accordance with information disclosure rules in a timely manner [1] - For any external investments or asset acquisitions, the company advises stakeholders to refer to formal announcements published in designated information disclosure media [1]

Core Viewpoint - International Medical plans to raise up to 1.008 billion yuan through a private placement of A-shares to no more than 35 specific investors, with funds allocated for smart healthcare projects, phase II of the proton therapy center, and to supplement working capital [1][2]. Group 1: Fundraising and Investment Projects - The total investment for the smart healthcare project is estimated at 751 million yuan, with 638 million yuan expected to be funded from the raised capital [1]. - The proton therapy center phase II project has a total investment of 99.9313 million yuan, with the entire amount to be funded from the raised capital [2]. - The company aims to leverage the "silver economy" and utilize idle assets for the smart healthcare project, which will enhance asset utilization [1]. Group 2: Market Demand and Strategic Positioning - The domestic cancer incidence rate has been rising, and proton therapy is becoming a key direction for high-end cancer treatment due to its precision and lower radiation to healthy tissues [2]. - There is a significant market gap for proton therapy centers in China, with only 7 operational centers by the end of 2024, and none in Northwest China, indicating a strategic opportunity for the company [2]. Group 3: Financial Health and Historical Performance - The company has experienced continuous losses from 2021 to 2024, with cumulative losses of 2.621 billion yuan, and a net loss of 294 million yuan in the first three quarters of 2025 [3]. - The company's asset-liability ratio was 67.95% at the end of 2022 and is projected to be 68.80% by September 2025, indicating a high level of financial leverage [2][3]. - Cash reserves have been declining, with a drop of 43.94% from the end of 2024 to the third quarter of 2025, highlighting liquidity concerns [3]. Group 4: Shareholder and Pledge Issues - The controlling shareholder has a high proportion of pledged shares, with 66.12% of their holdings pledged, representing 21.22% of the company's total share capital [3].

Core Viewpoint - International Medical (000516.SZ) has announced a plan to issue shares to specific investors in 2025, aiming to raise up to 1,007.54 million yuan for various projects and working capital [1][2]. Group 1: Share Issuance Details - The share issuance will target no more than 35 specific investors, including qualified institutional investors and individuals [1]. - The pricing for the shares will be set at no less than 80% of the average trading price over the 20 trading days prior to the issuance [1][2]. - The total number of shares to be issued will not exceed 30% of the company's total share capital before the issuance, amounting to a maximum of 671,669,025 shares [2]. Group 2: Fund Allocation - The funds raised will be allocated as follows: - Smart Health Project: 637.61 million yuan (63.28%) - Proton Therapy Center Phase II: 99.93 million yuan (9.92%) - Working Capital: 270 million yuan (26.80%) - The total investment for these projects is estimated at 1,121.26 million yuan [3]. Group 3: Company Financial Performance - As of the announcement date, the company's total share capital is 2,238,896,753 shares, with the actual controller holding 32.10% of voting rights [4]. - The company reported a revenue of 961.13 million yuan for the latest quarter, a decrease of 18.95% year-on-year, and a net loss attributable to shareholders of 128.69 million yuan [8][9]. - For the year-to-date, the company achieved a revenue of 2,995.44 million yuan, down 16.94% year-on-year, with a net loss of 293.66 million yuan [9][10]. Group 4: Historical Financial Trends - The company has experienced a continuous decline in net profit over the past seven years, with the latest figures showing a net loss of 2.54 billion yuan for 2024, compared to a loss of 3.68 billion yuan in 2023 [10]. - The operating cash flow for the year-to-date is reported at 921.00 million yuan, reflecting a year-on-year increase of 47.67% [9][10].

Group 1 - The company, International Medicine (000516), announced on December 3 that it plans to issue shares to specific investors to raise no more than 1.008 billion yuan [1] - The raised funds will be allocated to the Smart Health Care Project, the second phase of the Proton Therapy Center, and to supplement working capital [1]

Group 1 - The company plans to raise a total of no more than 1.008 billion yuan through a private placement of shares [1] - The raised funds will be allocated to the smart healthcare project, the second phase of the proton therapy center project, and to supplement working capital [1]